Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer

被引:99
作者
Doi, Ryuichiro [1 ]
Kami, Kazuhiro [1 ]
Ito, Daisuke [1 ]
Fujimoto, Koji [1 ]
Kawaguchi, Yoshiya [1 ]
Wada, Michihiko [1 ]
Kogire, Masafumi [1 ]
Hosotani, Ryo [1 ]
Imamura, Masayuki [1 ]
Uemoto, Shinji [1 ]
机构
[1] Kyoto Univ, Dept Surg, Sakyo Ku, Kyoto 6068507, Japan
关键词
D O I
10.1007/s00268-005-0730-5
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The survival curve of patients who undergo surgical resection of pancreatic cancer displays a steep decline within 1 year and a relatively slow decline thereafter. The patients with a short survival time may have identifiable clinicopathologic factors that lead to rapid relapse. Study Design: We analyzed clinicopathologic factors in 133 patients who underwent margin-negative pancreatoduodenectomy with extended radical lymphadenectomy for invasive ductal carcinoma of the pancreas to detect factors that could be responsible for the short survival. Results: Tumor size, invasion of the anterior pancreatic capsule, retroperitoneal invasion, portal venous invasion, major arterial invasion, and metastasis to the para-aortic lymph nodes were variables associated with survival time in univariate analysis. Metastasis to the para-aortic lymph nodes was the single independent factor with a significant association with mortality in multivariate analysis. Some 84% of the patients who had positive para-aortic lymph nodes died within 1 year, versus 46% of the patients with negative nodes. Conclusions: Although tumors that involve the para-aortic lymph nodes may technically be resectable, the expected postoperative survival time for most patients is less than 1 year. If paraaortic nodal metastasis is detected, alternative treatment strategies should be considered.
引用
收藏
页码:147 / 154
页数:8
相关论文
共 48 条
[1]   ADJUVANT COMBINATION CHEMOTHERAPY (AMF) FOLLOWING RADICAL RESECTION OF CARCINOMA OF THE PANCREAS AND PAPILLA OF VATER - RESULTS OF A CONTROLLED, PROSPECTIVE, RANDOMIZED MULTICENTER STUDY [J].
BAKKEVOLD, KE ;
ARNESJO, B ;
DAHL, O ;
KAMBESTAD, B .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (05) :698-703
[2]  
Benassai G, 2000, Chir Ital, V52, P263
[3]   Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas [J].
Brennan, MF ;
Kattan, MW ;
Klimstra, D ;
Conlon, K .
ANNALS OF SURGERY, 2004, 240 (02) :293-298
[4]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[5]   100 AND 45 CONSECUTIVE PANCREATICODUODENECTOMIES WITHOUT MORTALITY [J].
CAMERON, JL ;
PITT, HA ;
YEO, CJ ;
LILLEMOE, KD ;
KAUFMAN, HS ;
COLEMAN, J ;
HERRINGTON, JL ;
MASON, GR ;
BRADLEY, EL ;
JORDAN, GL ;
GADACZ, TR ;
VANHEERDEN, JA ;
WATKINS, GH ;
COPELAND, EH .
ANNALS OF SURGERY, 1993, 217 (05) :430-438
[6]   Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer [J].
Crane, CH ;
Janjan, NA ;
Evans, DB ;
Wolff, RA ;
Ballo, MT ;
Milas, L ;
Mason, K ;
Charnsangavej, C ;
Pisters, PWT ;
Lee, JE ;
Lenzi, R ;
Vauthey, JN ;
Wong, A ;
Phan, T ;
Nguyen, Q ;
Abbruzzese, JL .
INTERNATIONAL JOURNAL OF PANCREATOLOGY, 2001, 29 (01) :9-18
[7]   Survival among patients with adenocarcinoma of the pancreas: A population-based study (United States) [J].
Cress, RD ;
Yin, DX ;
Clarke, L ;
Bold, R ;
Holly, EA .
CANCER CAUSES & CONTROL, 2006, 17 (04) :403-409
[8]   Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer [J].
de Lange, SM ;
van Groeningen, CJ ;
Meijer, OWM ;
Cuesta, MA ;
Langendijk, JA ;
van Riel, JMGH ;
Pinedo, HM ;
Peters, GJ ;
Meijer, S ;
Slotman, BJ ;
Giaccone, G .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (09) :1212-1217
[9]   AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma [J].
DiMagno, EP ;
Reber, HA ;
Tempero, MA .
GASTROENTEROLOGY, 1999, 117 (06) :1464-1484
[10]  
EDGE SB, 1993, CANCER-AM CANCER SOC, V71, P3502, DOI 10.1002/1097-0142(19930601)71:11<3502::AID-CNCR2820711107>3.0.CO